Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;12(1):58-71.
doi: 10.2174/1874471012666190102165053.

[18F]Amylovis as a Potential PET Probe for β-Amyloid Plaque: Synthesis, In Silico, In vitro and In vivo Evaluations

Affiliations

[18F]Amylovis as a Potential PET Probe for β-Amyloid Plaque: Synthesis, In Silico, In vitro and In vivo Evaluations

Suchitil Rivera-Marrero et al. Curr Radiopharm. 2019.

Abstract

Background: Alzheimer's disease (AD) is the most common form of dementia. Neuroimaging methods have widened the horizons for AD diagnosis and therapy. The goals of this work are the synthesis of 2-(3-fluoropropyl)-6-methoxynaphthalene (5) and its [18F]-radiolabeled counterpart ([18F]Amylovis), the in silico and in vitro comparative evaluations of [18F]Amylovis and [11C]Pittsburg compound B (PIB) and the in vivo preclinical evaluation of [18F]Amylovis in transgenic and wild mice.

Methods: Iron-catalysis cross coupling reaction, followed by fluorination and radiofluorination steps were carried out to obtain 5 and 18F-Amylovis. Protein/Aß plaques binding, biodistribution, PET/CT Imaging and immunohistochemical studies were conducted in healthy/transgenic mice.

Results: The synthesis of 5 was successful obtained. Comparative in silico studies predicting that 5 should have affinity to the Aβ-peptide, mainly through π-π interactions. According to a dynamic simulation study the ligand-Aβ peptide complexes are stable in simulation-time (ΔG = -5.31 kcal/mol). [18F]Amylovis was obtained with satisfactory yield, high radiochemical purity and specific activity. The [18F]Amylovis log Poct/PBS value suggests its potential ability for crossing the blood brain barrier (BBB). According to in vitro assays, [18F]Amylovis has an adequate stability in time. Higher affinity to Aβ plaques were found for [18F]Amylovis (Kd 0.16 nmol/L) than PIB (Kd 8.86 nmol/L) in brain serial sections of 3xTg-AD mice. Biodistribution in healthy mice showed that [18F]Amylovis crosses the BBB with rapid uptake (7 %ID/g at 5 min) and good washout (0.11±0.03 %ID/g at 60 min). Comparative PET dynamic studies of [18F]Amylovis in healthy and transgenic APPSwe/PS1dE9 mice, revealed a significant high uptake in the mice model.

Conclusion: The in silico, in vitro and in vivo results justify that [18F]Amylovis should be studied as a promissory PET imaging agent to detect the presence of Aβ senile plaques.

Keywords: Alzheimer's disease diagnosis; docking and dynamic simulations; fluorine-18; iron cross-coupling reaction; positron emission tomography; β-amyloid probe..

PubMed Disclaimer

Figures

Scheme 1
Scheme 1
General procedure for the synthesis of 2-(3-fluoropropyl)-6-methoxynaphthalene (5) and [18F]Amylovis. All reported yields correspond to purified products.
Fig. (1)
Fig. (1)
A: Flexible docking of 5 (at 5 Å distance): the π-π hydrophobic interactions were located between the naphthyl ring of 5 and the phenyl ring of the F19 and F20 residues. B: Flexible docking of PIB (at 5 Å distance): the H-bond was located between nitrogen atom of the benzothiazole ring of PIB and hydrogen atom of -NH2 group of K16, and also a π-π hydrophobic interaction was located between the phenyl rings of PIB and F19.
Fig. (2)
Fig. (2)
Molecular Dynamics (MD) study II of 2-(3-fluoropropyl)-6-methoxynaphthalene (5). A: Evolution of different conformations of the ligand-Aβ1-42 peptide complex (at 10 Å) during different times. B: Root Mean Square Deviation (RMSD) of 5 position with respect to the Aβ peptide. C: Van der Waals (red) and electrostatic (green) energies for ligand-Aβ peptide complex at each time interval during MD simulations.
Fig. (3)
Fig. (3)
HPLC chromatograms of 5 (A) and [18F]Amylovis (B) after purification with C18 light-SPE cartridge, retention times: 8.5 and 8.7 min, respectively, and a purity > 99% for both compounds. Chromatographic conditions: Phenomenex Luna C18 (250 x 4.6 mm, 5 µm) column; mobile phase: AcN:H2O (75:25); flow rate: 1 mL/min.
Fig. (4)
Fig. (4)
Biodistribution of [18F]Amylovis in healthy Balb/C male mice (10-12 week-old and 28.5±2.0 g). %ID/g (percentage injected dose per gram tissue).
Fig. (5)
Fig. (5)
Comparative standardized uptake value relative (SUVr) curves (cortex/cerebellum) of [18F]Amylovis in healthy (control) vs APPSwe/PS1dE9 mice up to 130 min. Each point represents mean values ± standard deviation (n=4).
Fig. (6)
Fig. (6)
I. Comparison of standardized uptake values in regard to the brain stem, SUVr, of [18F]Amylovis in some brain regions between control healthy and APPSwe/PS1dE9 mice (n=3). II. Representative microphotograph of the prefrontal cortex (A, F), hippocampus (B, G), striatum (C, H), thalamus (D, I) and cerebellum (E, J). Set of images A-E corresponds to healthy animals and F-J to transgenic APPSwe/PS1dE9 mice (scale bar = 400 µm).

Similar articles

Cited by

References

    1. Selkoe D.J., Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 2016;8(6):595–608. - PMC - PubMed
    1. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–292. - PMC - PubMed
    1. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T., Hardy J., Hutton M., Kukull W. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 1996;2(8):864–870. - PubMed
    1. Monsonego A., Weiner H.L. Immunotherapeutic approaches to Alzheimer’s disease. Science. 2003;302(5646):834–838. - PubMed
    1. DeKosky S.T., Marek K. Looking backward to move forward: Early detection of neurodegenerative disorders. Science. 2003;302(5646):830–834. - PubMed